Le Lézard
Classified in: Health
Subjects: CCA, ACC

Early publication of Essity's Interim Report for quarter 1, 2022


STOCKHOLM, April 21, 2022 /PRNewswire/ -- Essity's Interim Report for quarter 1, 2022 will be published on Friday, April 22, 2022, at approximately 07:00 CET instead of Thursday, April 28, 2022 as previously communicated. In conjunction with publication, a telephone and web presentation will be held at 09:00 CET where President and CEO Magnus Groth will present and answer questions.

Presentation:

Date: Friday, April 22, 2022
Time: 09:00 CET
Link to Web presentation: https://essity.videosync.fi/2022-04-22

Telephone: +44 333 300 08 04 or +1 631 913 14 22 or +46 8 566 426 51. Please call in well in advance of the start of the presentation. State pin code: 70624732#

The presentation of the Interim Report will also be available on LinkedIn and Twitter

For further information, please contact:
Per Lorentz, Vice President Corporate Communications, +46 733 13 30 55, per.lorentz@essity.com
Johan Karlsson, Vice President Investor Relations, +46 705 11 15 81, johan.ir.karlsson@essity.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/essity/r/early-publication-of-essity-s-interim-report-for-quarter-1--2022,c3550576

The following files are available for download:

https://mb.cision.com/Main/15798/3550576/1567218.pdf

Early publication of Essityâ?tms Interim Report for quarter 1, 2022

SOURCE Essity


These press releases may also interest you

at 05:00
Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 92...

at 05:00
Element Biosciences Inc., developer of the Element AVITITM System, a new and disruptive DNA sequencing platform, announced today it will implement no price increases to the entire range of AVITI reagents, including the sequencing kit, the AdeptTM and...

at 04:44
On August 9, 2022, Asieris Pharmaceuticals, a global biopharmaceutical company specializing in the discovery and development of innovative drugs for the treatment of genitourinary tumors and other major diseases, announced that the multinational...

at 04:15
Medical publishing is the process of distributing the information and data of medical research in an effective and transparent way. Healthcare providers make use of that information to provide enhanced treatment and care to patients....

at 04:10
Researchers from Vancouver, British Columbia today examine the effect of duration of past exposure to air pollution with lung cancer diagnosis in new research presented at the IASLC World Conference on Lung Cancer 2022....

at 04:00
Through its combined forces, Sartorius and Albumedix will accelerate the availability of critical components for the manufacture of advanced therapies and next-generation biopharmaceuticals, globally.The Albumedix Campus in Nottingham, UK will be...



News published on 21 april 2022 at 12:52 and distributed by: